Amicus Therapeutics Inc
NASDAQ:FOLD 9:32:19 AM EDT
| Market Cap (Intraday) | 2.73B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $10.53 |
| 50-Day MA | $10.89 |
| 200-Day MA | $11.23 |
Amicus Therapeutics Inc Stock, NASDAQ:FOLD
3675 Market Street, Philadelphia, Pennsylvania 19104
United States of America
Phone: +1.215.921.7600
Number of Employees: 483
Description
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.